ACT Biotech, Inc. (ACTBio)

Oncology Corporate Profile

HQ Location

717 Market Street, Suite 650
San Francisco, CA 94103

Company Description

ACT Biotech is a biopharmaceutical company focused on the development and commercialization of highly targeted, oral cancer drugs. ACT's lead product candidate is telatinib. Telatinib showed robust antitumor activity with a solid safety profile in a Phase 2 clinical trial in stomach cancer. These results have triggered ACT to move telatinib to Phase 3 development. Telatinib has shown encouraging antitumor activity in a broad clinical trial program as a single agent in colorectal, kidney, stomach and liver cancers. Based on the encouraging efficacy and safety profile to date in a Phase 2 chemotherapy combination trial, ACT is advancing telatinib for untreated stomach cancer patients in a Phase 3 study, expected to be initiated this year. In addition to telatinib, the company's product pipeline includes three other oncology candidates. ACT Biotech is headquartered in San Francisco, CA, and backed by NGN Capital.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
telatinibVEGFR/PDGFR/KIT inhibitor1st line metastatic Gastric cancerIII
telatinibVEGFR/PDGFR/KIT inhibitorColorectal cancerI
ACTB1003Pan-FGFR and PI3K inhibitorVarious cancer typesI
ACTB1010aurora A and B inhibitorVarious cancer typesPreclinical
ACTB1011BCR/ABL inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display